December 09, 2024

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

In a pooled analysis of long-term outcomes reported in the Journal of Clinical Oncology, Long et al found that nivolumab plus ipilimumab was associated with better overall survival vs nivolumab monoth...

The ASCO Post

November 26, 2024

Highlights From the ESMO Congress 2024

The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highli...

The ASCO Post

January 05, 2024

Rare T Cells May Help Predict Immunotherapy Response in Patients With Skin Cancer

Researchers investigated the potential of a rare subset of T cells to predict which patients with advanced skin cancer may be responsive to immunotherapy.

The ASCO Post

February 19, 2024

FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma

On February 16, the FDA granted accelerated approval to lifileucel (Amtagvi), a tumor-derived autologous T-cell immunotherapy, for previously treated adult patients with unresectable or metastatic mel...

The ASCO Post

June 23, 2023

Expert Point of View: Zeynep Eroglu, MD

Dr. Zeynep Eroglu discusses the remarkable response of desmoplastic melanoma to pembrolizumab and proposes potential approaches for therapy and surgery.

The ASCO Post

April 17, 2023

Single-Agent Pembrolizumab May Benefit Patients With Advanced Desmoplastic Melanoma

Monotherapy with pembrolizumab led to clinical responses in 89% of patients with unresectable metastatic desmoplastic melanoma, according to results from the phase II S1512 clinical trial presented by...

The ASCO Post

September 19, 2023

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical Oncology, Adi Diab, MD, and colleagues investigated the addition of bempegaldesleukin, a pegylated interleukin-2 cytokine prodru...

The ASCO Post

August 05, 2024

FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma

On August 2, the FDA granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for a...

The ASCO Post

August 12, 2024

Pattern in Protein Production May Be Predictive of Side Effects From Immunotherapy in Patients With Melanoma

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases may predict the occurrence of severe side effects from immunotherapy in patients with melanoma.

The ASCO Post